Objectives: To update the evidence for associations between antibiotic classes and hospital-acquired Clostridium difficile infection (HA-CDI).
Introduction
Clostridium difficile is the leading cause of healthcare facility (HCF)-associated diarrhoea, estimated to cost the USA more than $3 billion per year. 1 Susceptibility to infection with C. difficile is induced by exposure to factors that disrupt gut microflora, most usually antibiotics that are commonly used in HCFs. Our earlier systematic review of the published literature up to 2001 found that clindamycin and third-generation cephalosporins were most strongly associated with HCF-associated C. difficile infection (HA-CDI).
Science (incorporated 2003) . The reference lists of the articles were examined.
All the searches were limited to studies published from 1 January 2002 to 31 December 2012 that reported on human participants. Primary literature searches were conducted using MeSH and Emtree terms and keywords in all fields: Clostridium difficile, diarrhea, diarrhoea, colitis, antibacterial agents, anti-infective agents, antibiotic, antimicrobial, casecontrol studies, cohort studies, retrospective studies and prospective studies (see the full search strategy in the Supplementary data at JAC Online). Searches of theses and dissertations used the terms Clostridium difficile, epidemiology and public health. Conference abstracts were searched using the terms Clostridium difficile, antibiotic, antimicrobial and risk factors.
Inclusion and exclusion criteria were developed using the Patients, Interventions, Comparisons and Outcomes approach. 7 Studies were included in the review if they met the following criteria: observational studies conducted among hospital inpatients, measurement of antibiotic exposure, inclusion of a comparison group and outcome of HA-CDI. We 670 records identified through database searching Records excluded (n = 161)
Primary literature: n = 121
Dissertations: n = 18
Conference proceedings: n = 22
• Not adult hospital inpatients (n = 37)
• Not antibiotics/classes (n = 41)
• No comparison group (n = 27)
• Not CDI (n = 16) or HA-CDI (n = 26)
• Other, e.g. duplicate study, review, insufficient data (n = 14)
Records after duplicates removed (n = 226) Figure 1 . PRISMA flow diagram.
Systematic Review Systematic Review excluded studies of cases only, studies assessing risk factors for severe disease, relapsing CDI or asymptomatic colonization and studies addressing CA-CDI or that did not properly exclude cases of community-acquired infection. Studies that did not examine specific antibiotics or antibiotic classes were also excluded. The review was limited to English-language studies, but non-English-language articles were included in searches and their abstracts were assessed for eligibility. Solely paediatric study populations were also excluded.
Screening and data abstraction
The abstracts were screened to eliminate irrelevant reports. Full-text articles of the remaining studies were assessed for eligibility. The authors of one study for which insufficient detail was presented were contacted; they were unable to provide the information and the study was excluded. Data were extracted by a single reviewer (C. S.). Study characteristics (citation, location, study period, study design, study population, case definition, antibiotic exposure, matching and adjustment method) were recorded. Data on the number of subjects (cases, non-cases, exposed or unexposed), unadjusted and adjusted effect sizes and 95% CIs were entered into an Excel spreadsheet. Antimicrobial agents were classified according to their therapeutic class: penicillins, cephalosporins, tetracyclines, trimethoprim/sulphonamides, macrolides, quinolones, aminoglycosides, lincosamides (clindamycin) and carbapenems. In studies that reported more than one exposure within each class, effect estimates were combined by taking the weighted average of the log ORs, with inverse variance weights.
Quality assessment
The quality of included studies was assessed based on the NewcastleOttawa Scale 9 (see Table S1 , available as Supplementary data at JAC Online), modified to represent issues specific to CDI. 10 Study power was calculated from unadjusted effect sizes.
Statistical analysis
Analyses were undertaken using STATA v12.1 using the 'metan', 'metabias' and 'metareg' packages.
11
A pooled random effects analysis using the DerSimonian-Laird approach 12 was used to assess the risk of HA-CDI associated with antibiotic classes relative to no exposure. The most fully adjusted OR was used. A secondary analysis considered the risk associated with penicillin and cephalosporin subclasses. Estimates were weighted by the inverse of the variance. Heterogeneity of pooled effects was assessed using the I 2 statistic; 13 a P value ,0.1 was defined as the presence of heterogeneity. 7 Study factors identified a priori were explored as sources of heterogeneity using meta-regression consisting of: location (North America, Europe, Australia), study period (up to and including 2002, post-2002), whether it was conducted during a CDI outbreak, the time period of measurement of antibiotic exposure (during admission only, prior to admission and during admission), study quality (low, medium or high), number of key confounders considered (≤3, .3), the study sample (antibiotic exposed versus all inpatients) and the diagnostic test used [enzyme immunoassay (EIA) or other]. Sensitivity analyses were undertaken to explore causes of heterogeneity identified from meta-regression (P, 0.10).
Publication bias was assessed by generating funnel plots and tested used Egger's asymmetry test.
Results
A total of 569 non-duplicate records were screened for eligibility; 14 met the inclusion criteria, covering 15938 patients (Figure 1 ). 
Systematic Review

Description of included studies
There were 13 case-control studies and one cohort study (Table 1) . Ten studies were conducted in North America, three in Europe and one in Australia, spanning the period 1996-2009; eight studies were conducted after 2002 and three of these were conducted during CDI outbreaks. 4, 14, 15 The studies varied in size from 15 to 1142 cases of CDI. Most studies used hospital inpatients as their study population; four studies used an antibiotic exposed subpopulation. 14,16 -18 Although studies specifically based on paediatric populations were excluded, one study 19 included patients aged .2 years. All studies included symptomatic cases with a positive C. difficile assay. The most common diagnostic test was toxin A/B EIA in six studies. 14,16 -18,20,21 Definitions of HCF acquisition were .48 h (n¼6) 14,15,18,21 -23 and .72 h after admission (n¼7). 4,16,19,20,24 -26 Two studies incorporated previous contact with an HCF in their definition. 4, 23 Most studies (12/14) used asymptomatic controls. Three studies measured exposure during admission only, 17, 18, 23 while the remainder measured antibiotics received prior to and during the admission (28 days to 3 months). Only two studies evaluated all nine main antibiotic classes of interest. 16, 25 Ten studies reported various associations for subclasses of penicillins (n¼ 4), 14, 19, 21, 24 cephalosporins (n¼ 1) 22 or both (n ¼5). 4, 16, 20, 23, 25 Study quality was scored high for seven studies 14,16,18,22 -25 (see Table S2 available as Supplementary data at JAC Online). Studies with low to moderate scores experienced limitations across all three domains. All studies took into account at least some important confounders. Six studies addressed four or more confounders but not for every association examined. 4, 14, 16, 22, 23, 25 The most common confounders assessed were age, sex, length of stay and exposure to other antibiotics. Only five studies considered comorbidities. 4, 16, 18, 22, 23 Studies commonly failed to report details of a priori sample size calculations, and six studies 15,17,19 -21,26 either had insufficient power to detect any differences or did not report sufficient information to allow calculation. Figure 2 presents the pooled effects for exposure to the nine main antibiotic classes from case -control studies using non-diarrhoeal 
Pooled effects
Stratification by antibiotic subclass
There was a 50% (95% CI ¼ 1.05-2.24) increased risk of CDI associated with penicillin combination antibiotics but not for other penicillin subgroups (Figure 3 ). Second-, third-and fourth-, but not first-generation cephalosporins were also associated with two to three times the risk of CDI ( Figure 4) ; however, 
Meta-regression and sensitivity analyses
The study population was the most common source of heterogeneity (Table 2) , seen for trimethoprim/sulphonamides, third-generation cephalosporins and macrolides. Excluding studies based on antibiotic-exposed inpatients reduced the heterogeneity, except for macrolides, for which further analysis indicated that studies conducted after 2002 or those using antibiotic-exposed participants had 30% smaller effect sizes than other studies. The timing of antibiotic exposure measurement was a significant heterogeneity source for fluoroquinolones and aminoglycosides. The risk associated with fluoroquinolones fell from 66% to 39% after excluding one study that measured antibiotic exposure during hospital admission only. 23 The strongest predictor of heterogeneity for penicillin combinations was the definition of hospital acquisition: there was no significant association when analyses were restricted to 4/6 studies that used a definition of .72 h compared with studies using a definition of .48 h ( Table 2) .
The choice of diagnostic test was weakly associated with heterogeneity for first-generation cephalosporins, where studies that used toxin EIA tests had smaller effect sizes (OR¼ 1.04, 95% CI ¼ 0.88-1.24) than studies using other methods (2.08, 1.37 -3.17, n¼ 2 studies). For second-generation cephalosporins, there were higher associations for studies conducted after 2002 (4.08, 2.27-7.34).
Diarrhoea controls
Three studies included symptomatic patients who tested negative for C. difficile as controls. A calculation of crude effect sizes found smaller associations for the toxin-negative than the non-diarrhoeal control group in one study. 22 Asha et al. 19 reported a 4-fold increased risk associated with 'broad-spectrum' cephalosporins (OR¼3.8, 95% CI¼3.0-4.6). Vesta et al. 26 provided descriptive information only and, due to the matched design, precluded the calculation of effect estimates.
Cohort studies
One cohort study, consisting of 8000 adult inpatients exposed to antibiotics and followed up until 60 days post-discharge, was included. 18 
Non-English-language studies
Five out of 27 non-English language studies were eligible for inclusion at abstract screening (Table S3 available as Supplementary data at JAC Online). 27 -31 Of these, full texts of three articles were available, and two were eligible for inclusion following a full text review. The findings were generally consistent with those of studies published in English, with the strongest associations reported for clindamycin 31 and third-generation cephalosporins. 28 
Publication bias
For studies reporting results for the main antibiotic classes, the funnel plot ( Figure S1 available as Supplementary data at JAC Online) showed little evidence of publication bias. The result of Egger's test of small-study effects was not significant (P¼ 0.57).
Discussion
A systematic review and meta-analysis was undertaken to summarize the evidence for associations between antibiotic classes and the risk of HA-CDI. The findings indicate that third-generation cephalosporins remain the strongest antibiotic risk factor. The modest association seen for fluoroquinolone antibiotics is not surprising as they are more specifically related to C. difficile infections with the NAP1/RT027 fluoroquinolone-resistant epidemic strain. 
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Since our earlier review, the quality of studies has improved, reducing the threat of bias. However, four studies restricted their study populations to inpatients with recent antibiotic exposure, which are not representative of all HA-CDI cases, 14,16 -18 and one study used toxin-negative controls, which do not represent the source population of cases. 26 Bias relating to diagnostic suspicion remains problematic if those exposed to antibiotics are more likely to be tested for C. difficile; guidelines that recommend testing all hospitalized patients who develop diarrhoea should be followed. 33 There was a variation in the definition of HA-CDI, with only a small number of studies including recent contact with HCFs, 4, 23 according to guidelines, 34 and 27 studies were excluded from the review due to insufficient information regarding the acquisition of CDI.
There is a lack of consensus regarding the appropriate time window to measure antibiotic exposure giving rise to heterogeneity. Recent studies suggest the greatest risk is in the first 30 days but that it remains increased for up to 90 days. 22, 35 Furthermore, the number of antibiotics, dosage and duration of antibiotic exposure have all been previously identified as risk factors for CDI. 36 Residual confounding remains a potential issue as only a few studies took into account a sufficient number of confounding factors.
This study provides the most up-to-date and systematic synthesis of the literature in relation to the risk of HA-CDI associated with antibiotics. However, the results should be interpreted with caution as the number of studies contributing to any one analysis ranged from three to 10. Our study is limited by the availability of a single reviewer to select, extract and analyse the data. Continued improvements in the conduct of observational studies of CDI would be gained by following recommendations from the STROBE initiative. 37 The adoption of recently developed guidelines for the diagnosis and surveillance of CDI in future studies will also improve the quality of CDI epidemiological research.
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